Historical review on thymosin α1 in oncology: Preclinical and clinical experiences

Expert Opinion on Biological Therapy

Volumn 15, Issue , 2015, Pages 31-39

  Garaci, Enrico ^a,b   Pica, Francesca ^a   Matteucci, Claudia ^a   Gaziano, Roberta ^a   D’Agostini, Cartesio ^a   Miele, Martino Tony ^a   Camerini, Roberto ^c   Palamara, Anna Teresa ^b,d   Favalli, Cartesio ^a   Mastino, Antonio ^e   Serafino, Annalucia ^e   Vallebona, Paola Sinibaldi ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Faculty of Architecture and Industrial Design   (Italy)

^c Sigma Tau SpA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Cancer; Chemotherapy; Experimental tumor models; Immune modulation; Thymosin a1

Indexed keywords

ANTINEOPLASTIC AGENT; THYMOSIN ALPHA1; CYTOKINE; THYMOSIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNOGENICITY; LUNG CANCER; META ANALYSIS (TOPIC); METASTATIC MELANOMA; NONHUMAN; ONCOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR CELL; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; THYMOSIN;

EID: 84957792690     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1017466     Document Type: Review

References (45)

1. Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA 1972; 69: 1800-3
2. Low TL, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. J Biol Chem 1979; 254:987-95
3. Talmadge JE, Fidler IJ, Oldham RK. The NCI preclinical screen of biological response modifiers. Behring Inst Mitt 1984;74:189-94
4. Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci 2007; 1112:1-13
5. Chretien PB, Lipson SD, Makuch R, et al. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treat Rep 1978;62(11):1787-90
6. Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod 1985;4:147-58
7. Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann NY Acad Sci 2007;1112:225-34
8. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 2003;3(8):1145-50
9. Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 1985;20(3):189-92
10. Garaci E, Mastino A, Pica F, Favalli C. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother 1990;32:154-60
11. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 1992; 50(3):493-9
12. Garaci E, Pica F, Mastino A, et al. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J Immunother Emphasis Tumor Immunol 1993; 13(1):7-17
13. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 1998;18(5A):3571-8
14. Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 1994;57(5):701-5
15. Lopez M, Carpano S, Cavaliere R, et al. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 1994;5(8):741-66
16. Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Res 2000;10:189-92
17. Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010;28(10):1780-7
18. Garaci E, Lopez M, Bonsignore G, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 1995;31A (13 14):2403-5
19. Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Res 1996;16:1001-4
20. Jiang J, Wang X, Tian J, et al. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and metaanalysis of randomized controlled trials. Thoracic Cancer 2011;2:213-20
21. Tuthill CW, King RS. Thymosin apha 1 -- a peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol 2013;3:133
22. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998;45:209-15
23. Cheng S, Wu M, Chen H, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha 1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 2004;51:1445-7
24. Cheng SQ, Wu MC, Chen H, et al. Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments. Zhonghua Zhong Liu Za Zhi 2005; 27(3):183-5
25. Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology Int 2009;3(3):480-9
26. Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin-a1 stimulates maturation of CD34 stem cells into CD3 4 cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999;21:15-26
27. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 2009;9(5):593-08
28. Umeda Y, Sakamoto A, Nakamura J, et al. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother 1983;15:78-83
29. Pierluigi B, D’Angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci 2010;1194:1-5
30. Yao Q, Doan LX, Zhang R, et al. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunol Lett 2007; 110:110-20
31. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 2005;6:531-7
32. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004; 103:4232-9
33. Shrivastava P, Singh SM, Singh N. Effect of thymosin alpha 1 on the antitumor activity of tumor--associated macrophagederived dendritic cells. J Biomed Sci 2004;11:623-30
34. Shrivastava P, Singh SM, Singh N. Antitumor activation of peritoneal macrophages by thymosin alpha-1. Cancer Invest 2005; 23:316-22
35. Peng X, Zhang P, Wang X, et al. Signaling pathways leading to the activation of IKK and MAPK by thymosinalpha1. Ann NY Acad Sci 2007;1112:339-50
36. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10
37. Matteucci C, Minutolo A, Sinibaldi-Vallebona P, et al. Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann N Y Acad Sci 2010;194:6-19
38. Giuliani C, Napolitano G, Mastino A, et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000;30:778-86
39. Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 1993;53:5214-18
40. Moody TW, Tuthill C, Badamchian M, et al. Thymosin alpha1 inhibits mammary carcinogenesis in Fisher rats. Peptides 2002; 23:1011-14
41. Garaci E, Pica F, Serafino A, et al. Thymosin alpha and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 2012; 1269:26-33
42. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigenprocessing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-54
43. Chang CC, Ogino T, Mullins DW, et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2microglobulin loss-of-function in melanoma cells. J Biol Chem 2006;281:18763-73
44. Guadagni F, Graziano P, Roselli M, et al. Differential expression of a new tumor-associated antigen TLP, during human colorectal cancer tumorigenesis. Am J Pathol 1999;154:993-9
45. Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev 2011(2):CD003993